The UK's NHS could do much better - and so could the US

Interactive Artifact

What an Optimised NHS Prostate Cancer Strategy Would Actually Look Like

Informed Prostate Cancer Support Group  |  IPCSG

Special Report  ·  May 28, 2026

Companion Analysis  ·  Follows: "UK Narrows Prostate Cancer Screening to a Few Thousand Men" (IPCSG, May 28, 2026)

Policy Analysis

 

The UK's new screening programme will reach a few thousand men per year while 55,000 are diagnosed annually. The tools to do far better — polygenic risk scoring, multi-marker blood tests, precision MRI, and consistent active surveillance — already exist, are largely within NICE approvals, and are supported by compelling trial evidence. Here is the architecture of what an evidence-optimised system would build right now. 

 

IPCSG Newsletter Staff  ·  Sources: NEJM, Lancet Oncology, ASCO Post, ICR, Science Media Centre, Harvard T.H. Chan School of Public Health, Urology Times, PMC, GOV.UK

Key Points for Patients

• The UK NSC's new BRCA2-based criterion captures at most 2–3% of the heritable risk for prostate cancer. Polygenic architecture explains the other 97%.
• BARCODE1 (NEJM, April 2025) demonstrated that a saliva-based polygenic risk score (PRS) identified clinically significant prostate cancer in 40% of high-PRS men — with 55% classified as intermediate or high risk — at a biopsy positive predictive value comparable to BRCA2 screening.
• Of cancers detected in BARCODE1, 71.8% would have been missed entirely by the current UK diagnostic pathway, which requires both elevated PSA and a positive MRI.
• The Stockholm3 multi-marker blood test reduces unnecessary biopsies by 45% relative to PSA alone while maintaining detection of clinically significant disease — and is already validated in diverse ethnic populations including Black men.
• The ProtecT trial 15-year outcomes (NEJM, 2023) confirm that prostate cancer–specific survival at 15 years is virtually identical across active monitoring (96.6%), surgery (97.2%), and radiotherapy (97.7%) for screen-detected localised disease — supporting aggressive expansion of active surveillance to eliminate overtreatment harm.
• Prevention — diet, obesity, vitamin D, physical activity — remains almost entirely unaddressed by NHS public health strategy despite substantial evidence of modifiable risk.

The Coverage Gap: Why BRCA2 Alone Is Not Enough

When the UK National Screening Committee justified its decision to restrict prostate cancer screening to men with pathogenic BRCA2 variants plus qualifying family history, it was making an evidentially defensible argument about the group for which the harm-benefit balance is most clearly favourable. But it was simultaneously obscuring something important: BRCA2 pathogenic variants are responsible for only a fraction of the heritable risk for prostate cancer.

Unlike breast and ovarian cancer — where BRCA1 and BRCA2 together explain a substantial proportion of familial clustering — prostate cancer is one of the most heritable cancers in medicine (twin studies estimate 57% heritability, among the highest of any malignancy), but that heritability is almost entirely polygenic. It is distributed across hundreds of common genetic variants, each contributing a small increment of risk, that combine into large aggregate effects in the men who happen to inherit many of them together. BRCA1 and BRCA2 mutations combined explain roughly 2–3% of overall heritable prostate cancer risk. The other 97% is invisible to the NSC's new programme.

Family history, used as a proxy for this polygenic burden, is a blunt instrument. A man can carry extreme polygenic risk without any first-degree relative having been diagnosed — because relatives died of competing causes first, because their cancers were subclinical, or simply because of the probabilistic nature of polygenic inheritance. Conversely, a man with a father affected by prostate cancer may carry an entirely average polygenic risk profile — his father's cancer could have been predominantly environmental or sporadic. The current criteria thus systematically miss the highest-risk men while including some with only moderate elevation in risk.

• 2–3% Heritable prostate cancer risk explained by BRCA1/2 mutations combined
• 57% Estimated heritability of prostate cancer — one of the highest of any cancer
• 5.7× Elevated prostate cancer risk in men in the top 1% of polygenic risk score

Pillar One: Polygenic Risk Scoring — The Evidence Is Here

The most significant prostate cancer detection advance of the past decade received surprisingly little attention in the NSC's deliberations: the polygenic risk score, and specifically the BARCODE1 trial published in the New England Journal of Medicine in April 2025.

What BARCODE1 Found

BARCODE1, led by Professor Ros Eeles at The Institute of Cancer Research, London, was the first large-scale prospective trial to operationalise PRS-based prostate cancer screening in a real primary care setting. Men aged 55–69 across 69 GP practices were invited by letter to mail in a saliva sample. Of 40,292 invited, 6,393 returned samples; 745 men (11.7%) were found to have a PRS in the 90th percentile or higher and were invited for further evaluation — PSA testing, multiparametric MRI, and transperineal prostate biopsy.

The results were striking. Of the 468 men who proceeded to MRI and biopsy, 187 (40.0%) were diagnosed with prostate cancer — with a median PSA at diagnosis of just 2.1 ng/mL, far below the PSA threshold that would have triggered clinical investigation under current NHS protocols. More than half of cancers detected (55.1%) were classified as intermediate or high risk per 2024 NCCN criteria, warranting treatment. Of that group, 21.3% had unfavourable intermediate or high-risk disease.

The most consequential finding for NHS policy: 71.8% of the cancers detected by PRS screening would have been completely missed by the current UK diagnostic pathway, which requires both an elevated PSA and a positive MRI to trigger biopsy. These were real, clinically significant cancers — not Gleason 6 indolent lesions — being silently overlooked by the existing system.

"This study is the strongest evidence to date on the clinical utility of a polygenic score for prostate cancer screening. It shows that a polygenic score can improve early detection of clinically significant prostate cancer, including those warranting radical treatment. A large proportion of prostate cancer cases detected using a polygenic score would not have been detected using the current diagnostic pathway."

— Professor Michael Inouye, University of Cambridge, commenting on BARCODE1 for the Science Media Centre, April 2025

The Diagnostic Performance Comparison

In terms of positive predictive value — the proportion of screened men who actually have significant cancer at biopsy — PRS-based screening in BARCODE1 performed comparably to the IMPACT study's BRCA2 results that the NSC found compelling enough to base its entire programme on:

Screening Criterion	PPV for Any PCa at Biopsy	% Clinically Significant	Median PSA at Dx
BRCA2 variant (IMPACT study)	~48%	77%	~4.5 ng/mL
Top 10% PRS (BARCODE1)	40%	55.1% intermediate/high	2.1 ng/mL
PSA ≥3 ng/mL alone (ERSPC)	~24%	35.5%	Varied
Current UK pathway (PSA + MRI)	~60%	Higher specificity	Misses 72% of PRS-detected cases

The PRS criterion covers 10% of the male population rather than 0.3%. Its positive predictive value is comparable to the BRCA2 benchmark. It detects cancers at lower PSA values — meaning earlier, more curable stages. And unlike BRCA status, it captures the genetic architecture that actually drives most of the population's heritable prostate cancer risk.

Addressing the Equity Problem Through PRS

One of the most important developments arising from BARCODE1 is what comes next. Professor Eeles announced the rollout of PRODICT — an updated PRS test specifically designed for diverse populations, including Black men — acknowledging directly that the 130-SNP BARCODE1 panel was validated in men of European ancestry and needs ancestry-appropriate calibration for equitable deployment.

This work builds on a substantial multi-ancestry PRS literature. A 2022 meta-analysis across 31,925 cases and 490,507 controls from the VA Million Veteran Program and other diverse cohorts — including 8,794 African-ancestry cases — demonstrated that a multi-ancestry PRS meaningfully stratified risk in men of African, European, and Hispanic descent. Men in the top PRS decile carried 2.8-fold elevated risk in African-ancestry populations and 3.8-fold in European-ancestry populations — not as discriminating as in white men, but clinically significant and far superior to current selection criteria for Black men, which is effectively "no systematic screening at all."

A properly calibrated multi-ancestry PRS, combined with known baseline elevated risk in Black men, would create a risk stratification framework that both addresses the equity gap and resolves the NSC's stated evidentiary uncertainty about whether screening would do more good than harm in this population — not by ignoring the uncertainty, but by targeting the highest-risk individuals within the group where the harm-benefit balance is most clearly favourable.

Pillar Two: A Precision Detection Cascade

Even for men who are identified as elevated risk, the current NHS diagnostic pathway — elevated PSA triggering MRI, positive MRI triggering biopsy — has well-documented limitations. It misses cancers with PSA below the threshold, over-refers men with benign PSA elevation, and creates unnecessary biopsy harm. A properly architected detection cascade would layer multiple validated tools sequentially, removing men from the pipeline at each stage where further investigation would be harmful rather than helpful.

Stockholm3: The Under-Deployed Reflex Test

The Stockholm3 blood test combines PSA, five additional protein markers (free PSA, PSP94, GDF15, KLK2, and MIC-1), 101 genetic single-nucleotide polymorphisms, and clinical data (age, family history, prior biopsy status) into a single risk score. In the landmark STHLM3-MRI randomised trial published in The Lancet Oncology (2021) and with extended follow-up published in JAMA Network Open (2024), Stockholm3 demonstrated:

• Area under the ROC curve of 0.76 for detecting clinically significant prostate cancer, versus 0.60 for PSA alone
• Reduction in MRI referrals by 36% relative to PSA-based screening
• Reduction in biopsy procedures by 8% in the randomised comparison, while maintaining non-inferior detection of clinically significant cancer
• At a threshold of ≥15%, unnecessary biopsy reduction of 45% across the overall cohort — with comparable performance in Asian and Black subgroups (46% reduction) and Hispanic men (53% reduction)

Nine-year follow-up from the original STHLM3 trial, published in European Urology in October 2025, confirmed that Stockholm3-only elevation (PSA below threshold but Stockholm3 elevated) carried an 8.8-fold elevated hazard for high-risk biochemical recurrence compared with men with neither test elevated — confirming that Stockholm3 is not merely reducing biopsies by missing real cancers, but by accurately distinguishing the men who need investigation from those who do not.

Stockholm3 is already commercially available in the UK and has received NICE attention. It is not systematically deployed. Integrating it as a mandatory reflex test for men with PSA in the grey zone (2–10 ng/mL) before MRI is ordered would immediately reduce NHS radiology burden while improving the quality of biopsy referrals — at essentially no net cost, because the test cost is offset by reduced downstream MRI and biopsy expenditure.

The Prostagram: Fast MRI as a Screening Tool

The TRANSFORM trial is evaluating a shortened MRI protocol — the "prostagram" — designed to be fast enough and cheap enough for use as a screening-level investigation rather than a diagnostic one. Conventional multiparametric MRI takes 45–60 minutes and requires significant radiologist expertise to interpret. The prostagram concept reduces scan time to under 15 minutes using a biparametric protocol (T2-weighted and diffusion-weighted imaging only, without dynamic contrast enhancement), with AI-assisted reading to address radiologist capacity constraints.

The GÖTEBORG-2 trial (NEJM, 2022) demonstrated that screening using PSA followed by MRI with targeted biopsy only — without systematic biopsy — detected fewer insignificant cancers than PSA-plus-systematic biopsy (4.9% vs 12.7% of screened participants diagnosed with insignificant cancer) while maintaining comparable detection of clinically significant disease. This is the fundamental validation that MRI-first approaches reduce overdiagnosis without sacrificing sensitivity for the cancers that matter.

📊 AUC Comparison: How the Tools Stack Up for Aggressive Cancer Detection

A 2025 review synthesising recent trial data found the following discrimination performance (AUC) for detecting Gleason ≥7 (Grade Group ≥2) prostate cancer: PSA alone — 0.67; PRS from saliva (BARCODE1) — 0.85; AI-enhanced MRI (PRIME trial 2025) — 0.92. A combined PRS-plus-AI-MRI cascade approach may approach 0.92+ for the subset who reach imaging, while reducing the number who need imaging by stratifying through PRS first.

The Integrated Cascade: What an Optimised Programme Looks Like

Drawing on currently available tools — most of them either NICE-approved or CE-marked — an evidence-optimised NHS prostate cancer early detection programme would operate as a layered cascade. Each layer uses a progressively more resource-intensive investigation on a progressively smaller, higher-risk population. The design simultaneously expands coverage relative to BRCA2-only screening and reduces total system burden relative to population PSA screening.

• 1 Population PRS Stratification — Age 40 At routine GP registration or health check, offer saliva-based PRS to all men from age 40. One-time test, cost under £30 per person with current genotyping economics. Produces a lifetime risk percentile. BRCA1/2 and other pathogenic variant status is layered onto the polygenic background for combined absolute risk estimate. Men with established BRCA2 pathogenic variants and qualifying family history proceed directly to surveillance per current NSC guidance. Men with BRCA1 variants or top-decile PRS proceed to Layer 2
• 2 Risk-Stratified PSA Invitation Top 1% PRS (or combined risk equivalent to BRCA2): annual PSA from age 40. Top 2–10% PRS: biennial PSA from age 45. Top 10–25%: PSA discussion at shared decision-making consultation at age 50. Below median PRS: no systematic screening — proactively communicated to the patient to avoid anxiety-driven requests for unnecessary testing. Black men receive PRS assessment using a validated multi-ancestry panel; known baseline elevated risk is incorporated into the risk stratum assignment.
• 3 Stockholm3 Reflex Testing for PSA Grey Zone Any man with PSA between 2 and 10 ng/mL who does not have PSA above 10 ng/mL (where biopsy is indicated regardless) undergoes Stockholm3 testing before MRI referral. Men with Stockholm3 score below 15 and no other high-risk features are returned to surveillance with documented reassurance. This step alone reduces MRI referrals by approximately 36% and biopsy procedures by approximately 45% compared with PSA-triggered referral, based on STHLM3-MRI trial data.
• 4 Biparametric MRI (Prostagram Protocol) Before Any Biopsy Full adherence to current NICE guidance: no man proceeds to biopsy without MRI. The biparametric prostagram protocol — faster, cheaper, AI-assisted reading — is deployed for screening-context investigations; full multiparametric MRI reserved for PI-RADS 3 lesions requiring diagnostic clarification. Men with PI-RADS 1–2 and Stockholm3 below threshold return to surveillance. Men with PI-RADS 3–5 proceed to targeted biopsy
• 5 Targeted Transperineal Biopsy Only MRI-targeted transperineal biopsy for PI-RADS ≥3 lesions, with systematic biopsy of the anterior zone in high-risk individuals where MRI has known limitations. Transrectal systematic biopsy — the predominant NHS approach until recently — is retired; transperineal approach has superior sepsis profile and comparable or superior cancer detection. Cancer detected at this stage represents a population substantially enriched for clinically significant disease across all preceding filter stages.
• 6 Grade Group 1 and Low-Risk Grade Group 2 — Active Surveillance by Default Any Gleason 3+3=6 (Grade Group 1) diagnosis enters a structured national active surveillance programme automatically, with opt-out only after documented shared decision-making. Favourable intermediate risk (Grade Group 2, PSA <10, low volume) similarly defaults to AS per current NICE guidance. This step converts what was formerly overdiagnosis-into-overtreatment into overdiagnosis-into-observation — dramatically reducing the harm side of the screening ledger without requiring that fewer cancers be found.

Pillar Three: Active Surveillance Done Properly

The NSC's harm-benefit calculus treats overdiagnosis as a fixed harm — as if every detected indolent cancer automatically becomes a treated one. That assumption was true in 2003, when ERSPC began, and when radical prostatectomy or radiotherapy was the automatic response to any positive biopsy. It is substantially less true today, and could be made even less true with systematic national commitment to active surveillance.

What ProtecT Tells Us About the Treatment Trade-Off

The ProtecT trial — the largest randomised trial of treatment in screen-detected localised prostate cancer, funded by NIHR and conducted across the UK — published its 15-year outcomes in the New England Journal of Medicine in April 2023. The headline finding was unambiguous: prostate cancer-specific mortality at 15 years was statistically identical across active monitoring (3.1%), radical prostatectomy (2.2%), and radiotherapy (2.9%), with an overall P-value of 0.53. Overall survival rates were similarly comparable: 96.6%, 97.2%, and 97.7% respectively.

The trial did find more metastatic events in the active monitoring arm (approximately 9 per 100 versus 5 per 100 in the radical treatment arms) — a legitimate concern primarily for the intermediate and high-risk subgroups. But the critical insight is that one quarter of men in the active monitoring group were alive at 15 years without ever having received any form of treatment — and their prostate cancer-specific survival was comparable to men who were treated immediately.

Against this, the treatment arms generated substantial and sustained side-effect burdens that active monitoring completely avoided: higher rates of erectile dysfunction in the surgery arm, higher rates of bowel dysfunction in the radiotherapy arm, and urinary incontinence at rates substantially exceeding the monitoring arm throughout follow-up.

Where NHS Active Surveillance Fails in Practice

Despite NICE guidance recommending active surveillance for low-risk disease, AS implementation in the NHS is inconsistent, under-resourced, and inadequately supported. Specific failures include:

• Abandonment due to anxiety, not progression. ProtecT itself noted that a substantial proportion of men in the active monitoring arm elected treatment in early years without evidence of progression — "often reflecting anxiety on the part of either the patients or their physicians." The NHS provides essentially no systematic psychological support within AS programmes. Men who abandon AS prematurely for psychological rather than clinical reasons represent an avoidable conversion of overdiagnosis into overtreatment.
• No national AS registry. Unlike Sweden's NPCR or the U.S. consortium registries, the NHS has no systematic national database tracking AS outcomes. Without registry data, clinicians cannot identify which surveillance protocols are superior, which patients are progressing, or which subgroups are being undertreated. This is a significant structural failure.
• Inconsistent MRI integration into surveillance protocols. The shift from time-based systematic TRUS biopsy to MRI-triggered targeted biopsy within AS is occurring at some trusts but not others. MRI-targeted surveillance reduces the total number of confirmatory biopsies needed over a patient's surveillance career while improving the accuracy of reclassification — but access is a postcode lottery.
• Variation in AS eligibility criteria across trusts. Some NHS trusts are following AS pathways for Grade Group 1 only; others are appropriately extending it to favourable intermediate risk. No national standard is uniformly enforced, meaning a man's management can depend on geography as much as pathology.

⚠ The Overdiagnosis Calculus With Versus Without Robust AS

The NSC's harm-benefit model essentially assumed that overdiagnosed cancers lead to overtreatment at rates approximating historical data. If AS uptake for Grade Group 1 disease were 95%+ nationally — as the ProtecT data suggests it should be — the harm attributed to each overdiagnosis event drops to near zero: a biopsy cost, a surveillance programme cost, and some anxiety that structured support can substantially mitigate. The NSC's harm estimate is thus contingent on a level of NHS AS implementation that does not currently exist. Improving AS fidelity changes the harm-benefit calculation for screening without waiting for any new trial.

Pillar Four: Prevention — The Invisible Strategy

There is a foundational asymmetry in how the NHS approaches prostate cancer: enormous institutional energy is invested in the downstream question of what to do after diagnosis, while the upstream question of whether the cancer develops at all receives almost no systematic attention. This is not unique to the NHS — the U.S. system is no better — but it represents a missed opportunity whose scale is difficult to overstate.

What the Evidence Supports

Several modifiable risk factors for prostate cancer, and particularly for aggressive prostate cancer, have consistent epidemiological support:

Dietary pattern. The migrant studies comparing Japanese men in Japan to Japanese-Americans in Hawaii — conducted in the 1970s and subsequently replicated — established that prostate cancer incidence rises dramatically when men of East Asian ancestry adopt Western dietary patterns. This environmental contribution implies substantial prevention potential. The Mediterranean dietary pattern, characterised by high consumption of vegetables, legumes, olive oil, fish, and whole grains with low red and processed meat intake, is associated in multiple cohort studies with reduced cancer-specific and all-cause mortality in prostate cancer patients. A 2024 meta-analysis across 17 studies (up to February 2024) found moderate-certainty evidence that higher Mediterranean diet adherence was associated with reduced overall mortality in cancer patients (RR 0.96; 95% CI 0.94–0.98). The DINE study (NCT05590624, Case Comprehensive Cancer Center) is actively investigating the metabolic impact of controlled Mediterranean-type diets in men with prostate cancer on active surveillance, with completion anticipated in 2026.

Physical activity. Vigorous physical activity is specifically associated with reduced risk of aggressive prostate cancer (as opposed to indolent disease), across multiple large prospective cohort studies. A 2025 study in the American Journal of Epidemiology from Harvard T.H. Chan School of Public Health, using target trial emulation methods in the Health Professionals Follow-Up Study, evaluated World Cancer Research Fund/AICR recommendation-based physical activity and dietary strategies for prostate cancer prevention and found that sustained adherence to combined dietary and physical activity recommendations was associated with reduced long-term prostate cancer risk.

Obesity and metabolic health. Obesity — particularly central adiposity and metabolic syndrome — is associated with more aggressive prostate cancer and worse outcomes. The insulin/IGF-1 signalling axis and chronic inflammatory cytokine milieu associated with adipose tissue excess are biologically plausible mechanisms. Weight management and metabolic health interventions thus have dual benefit: reducing aggressive cancer risk and improving outcomes if cancer does develop.

Vitamin D. Epidemiological associations between vitamin D deficiency and elevated prostate cancer risk are consistent across populations. Men of African ancestry — who face the highest prostate cancer burden — are disproportionately vitamin D deficient due to higher melanin content reducing cutaneous synthesis at UK latitudes. This may contribute measurably to the observed disparity in prostate cancer incidence. Systematic vitamin D supplementation in Black men in the UK is neither expensive nor complex, and has cardiovascular and bone health benefits entirely independent of any cancer effect.

What Has Not Worked

The disappointing history of prostate cancer chemoprevention deserves acknowledgement. The SELECT trial (2011) tested selenium and vitamin E supplementation in 35,533 men and found not only no protective effect but a statistically significant increase in prostate cancer risk in the vitamin E arm. The PCPT trial showed finasteride (5-alpha reductase inhibitor) reduced overall prostate cancer incidence by 25%, but regulatory hesitation arose from a statistical excess of high-grade cancers in the finasteride arm — subsequently attributed largely to a biopsy detection bias rather than a genuine grade shift, but the perception persisted and killed the chemoprevention pathway commercially and clinically.

The lesson from SELECT and PCPT is not that prevention is impossible but that single-agent supplementation trials targeting biological pathways identified in observational studies frequently fail to translate into RCT-confirmed benefit — a familiar problem across cancer prevention research. Comprehensive lifestyle modification, which operates through multiple biological pathways simultaneously and lacks a single testable drug mechanism, is harder to evaluate in RCTs and correspondingly underinvested in.

What the NHS Is Actually Doing About Prevention

The honest answer is: almost nothing systematic. There is no public health campaign for prostate cancer prevention comparable to bowel cancer awareness, no dietary guidance specifically targeted at Black men or other high-risk groups, no organised lifestyle intervention programme embedded in GP practice for men with elevated PSA or high PRS results, and no integration of prevention counselling into existing NHS cancer screening pathways. Prevention programmes produce benefits on a 15–20 year horizon — beyond the political credit horizon of any current government — and generate no pharmaceutical revenue. The incentive structure works structurally against prevention investment.

The Insurance Logic Problem — and Its Solution

The NHS's approach to prostate cancer screening shares structural features with insurance actuarial logic: it aggregates costs and benefits at the population level, applies a fixed evidence threshold, and defers action until that threshold is met. This framework has genuine virtues — it prevents both premature adoption of harmful interventions and capture of policy by advocacy pressure. But it has two structural failures when applied to prostate cancer in 2026.

First, it accounts inadequately for the downstream costs of non-intervention. Late-stage prostate cancer is enormously expensive to manage: radioligand therapy, novel androgen receptor pathway inhibitors, PARP inhibitors for BRCA-mutated mCRPC, bone-modifying agents, supportive care. A 2024 modelling study estimated costs per quality-adjusted life year of approximately $50,000 for PSA-based screening, $32,000 for PRS-based screening, and $28,000 for AI-MRI-based screening — suggesting that precision screening approaches are not only clinically superior to PSA alone but potentially more cost-effective per QALY than the status quo of no programme. The SCHARR model that underpinned the NSC decision was criticised by Prostate Cancer Research for using a narrow economic lens that did not adequately reflect the burden and cost of metastatic disease. If the model were rerun with the full downstream cost of the cancers that screening would prevent, the prevention side of the ledger looks substantially better.

Second, population-level expected value calculations are ethically neutral with respect to distribution. The NSC's decision produces an outcome where the groups with the highest burden — Black men, men in deprived areas — receive the least intervention, because the evidentiary gap for those groups is partly a consequence of historical under-representation in research. Using absence of evidence as justification for absence of intervention in a group whose evidence gap is itself a product of systemic neglect is not evidence-based medicine. It is an equity failure dressed in methodological language.

The solution to both problems is not to abandon evidence standards but to enrich them: incorporate downstream cost accounting into the harm-benefit model, apply equity weighting to risk groups that have been systematically underserved by research, and use the tools that already exist — PRS, Stockholm3, MRI triage, structured AS — to move the system toward an architecture that the current evidence substantially supports right now, without waiting years for TRANSFORM to provide the RCT confirmation that a more ambitious committee would have had the institutional courage to act on today.

What IPCSG Members Can Do

This analysis is offered not as counsel of despair but as a map of the gap between where policy is and where the evidence points. For individual patients and their families, the following are actionable now:

• Know your genetic risk. If you have not had germline genetic testing — BRCA1, BRCA2, ATM, CHEK2, HOXB13, and Lynch syndrome genes — and you have a personal or family history of prostate, breast, ovarian, or pancreatic cancer, ask your physician or urologist about testing. In the U.S., testing is broadly covered by insurance for men with prostate cancer diagnoses. UK men with qualifying family history may be eligible through NHS clinical genetics services.
• Ask about PRS. Commercial PRS panels for prostate cancer risk are available in both the UK and U.S. through direct-to-consumer genomics companies and through research pathways. Results should be interpreted with a genetic counsellor or informed clinician. Men in the top decile of PRS have risk profiles that warrant earlier and more systematic PSA surveillance than current average-risk guidelines recommend.
• If on active surveillance, insist on MRI-guided protocols. Surveillance that relies solely on PSA and time-based systematic TRUS biopsy is suboptimal. Ask your urologist whether MRI-targeted biopsy is available and whether you can be referred to a centre with a formal AS programme and registry participation.
• Engage with lifestyle modification seriously. The Mediterranean diet evidence, physical activity data, and vitamin D literature may not be RCT-proven for prostate cancer prevention specifically, but the cumulative biological plausibility is strong and the interventions carry cardiovascular and metabolic benefits that are entirely independent of any cancer effect. This is the one dimension of the strategy where individuals have direct agency.
• For UK members specifically: TRANSFORM is enrolling. Men aged 50–74 (or 45–74 for certain risk groups) across the UK are being invited through their GPs to participate. Participation directly contributes to the evidence base that will determine whether broader screening — including Black men and men with family history — becomes NHS policy within the next 2–3 years.

Conclusion: The Evidence Gap Is Smaller Than the Policy Gap

The NSC's BRCA2-focused recommendation is a cautious, evidence-respecting step in the right direction. But the gap between where the policy landed and where the scientific evidence points is considerably larger than the committee's framing suggested. BARCODE1 demonstrated PRS-based screening performance comparable to the BRCA2 benchmark that underpins the new programme. Stockholm3 is ready to deploy. MRI-first pathways are NICE-approved. Active surveillance, rigorously implemented, dramatically reduces the overdiagnosis harm that has paralysed screening policy for two decades. And prevention — cheap, scalable, with no waiting for trial maturation — receives no systematic NHS investment whatsoever.

The tools to do dramatically better are largely on the shelf. What is missing is not evidence but institutional will: to move beyond PSA-era frameworks, to weight downstream costs properly, to apply equity obligations to the populations most burdened by the disease, and to act on the considerable evidence already available rather than deferring every decision to the next trial cycle.

Twelve thousand men will die of prostate cancer in the UK this year. Most of them did not have to.

Sources and Formal Citations

1. McHugh JK, Bancroft EK, Saunders E, et al. Assessment of a Polygenic Risk Score in Screening for Prostate Cancer. New England Journal of Medicine. 2025;392(14):1406–1417. doi:10.1056/NEJMoa2407934.
   https://www.nejm.org/doi/full/10.1056/NEJMoa2407934
2. Science Media Centre. Expert Reaction to the BARCODE1 Trial Assessing the Use of a Polygenic Risk Score in Screening for Prostate Cancer. April 9, 2025.
   https://www.sciencemediacentre.org/expert-reaction-to-the-barcode1-trial-assessing-the-use-of-a-polygenic-risk-score-in-screening-for-prostate-cancer/
3. OncLive Staff. Prostate Cancer Testing Via Polygenic Risk Score Outperforms Standard Approaches. OncLive, April 2026.
   https://www.onclive.com/view/prostate-cancer-testing-via-polygenic-risk-score-outperforms-standard-approaches
4. Urology Times Staff. Polygenic Risk Score May Identify More Clinically Significant PCa Than PSA, MRI. Urology Times, April 2025.
   https://www.urologytimes.com/view/polygenic-risk-score-may-identify-more-clinically-significant-pca-than-psa-mri
5. Eeles RA, Bancroft EK, McHugh JK, et al. Effect of Polygenic Risk Score for Clinically Significant Prostate Cancer in a Screening Program: The BARCODE1 Study Results. Journal of Clinical Oncology. 2024;42:10500. doi:10.1200/JCO.2024.42.16_suppl.10500.
   https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10500
6. Chen F, Darst BF, Madduri RK, et al. Validation of a Multi-Ancestry Polygenic Risk Score and Age-Specific Risks of Prostate Cancer: A Meta-analysis Within Diverse Populations. eLife. 2022;11:e78304. doi:10.7554/eLife.78304.
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322982/
7. Eklund M, Jäderling F, Discacciati A, et al. Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies (STHLM3-MRI): A Prospective, Population-Based, Randomised, Open-Label, Non-Inferiority Trial. Lancet Oncology. 2021;22(9):1240–1249. doi:10.1016/S1470-2045(21)00348-X.
   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00348-X/abstract
8. Nordström T, Annerstedt M, Glaessgen A, et al. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial. JAMA Network Open. 2024;7(2):e2354577. doi:10.1001/jamanetworkopen.2023.54577.
   https://pubmed.ncbi.nlm.nih.gov/38324313/
9. Björnebo L, Discacciati A, Falagario U, et al. Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial. European Urology. 2025; doi:10.1016/j.eururo.2025.09.XXX.
   https://www.sciencedirect.com/science/article/pii/S0302283825047359
10. UroToday. SUO 2024: Prostate Cancer Screening with Biomarkers and MRI — A European Perspective (STHLM3-MRI multi-ethnic validation data). December 6, 2024.
    https://www.urotoday.com/conference-highlights/suo-2024/suo-2024-prostate-cancer/156745-suo-2024-prostate-cancer-screening-with-biomarkers-and-mri-a-european-perspective.html
11. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine. 2023;388(17):1547–1558. doi:10.1056/NEJMoa2214122.
    https://www.nejm.org/doi/full/10.1056/NEJMoa2214122
12. ASCO Post Staff. Active Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer: 15-Year Outcomes in the UK ProtecT Trial. March 2023.
    https://ascopost.com/news/march-2023/active-monitoring-surgery-or-radiotherapy-for-localized-prostate-cancer-15-year-outcomes-in-the-uk-protect-trial/
13. Hugosson J, Månsson M, Wallström J, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. New England Journal of Medicine. 2022;387(23):2126–2137. doi:10.1056/NEJMoa2209454.
14. Guo F, McGee EE, Chiu Y-H, Giovannucci E, Mucci LA, Dickerman BA. Evaluating Recommendation-Based Dietary and Physical Activity Strategies for Prostate Cancer Prevention: A Target Trial Emulation in the Health Professionals Follow-up Study. American Journal of Epidemiology. 2025;194(2):449–459. doi:10.1093/aje/kwae184.
    https://pubmed.ncbi.nlm.nih.gov/38973750/
15. Di Maso M, Augustin LSA, Toffolutti F, et al. Adherence to Mediterranean Diet, Physical Activity and Survival after Prostate Cancer Diagnosis. Nutrients. 2021;13(1):243. doi:10.3390/nu13010243.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829941/
16. Prostate Cancer Research. UK NSC's Draft Recommendations on Prostate Cancer Screening: Our Response. March 13, 2026.
    https://www.prostate-cancer-research.org.uk/uk-nscs-draft-recommendations-our-response/
17. AUO ASMEPress. Saliva-Based Polygenic Risk Scores and AI-Enhanced Imaging for Prostate Cancer Screening Beyond PSA. 2025. (2024 modelling study: costs per QALY comparison PSA vs PRS vs AI-MRI.)
    https://auo.asmepress.com/articles/new-93-991.html
18. Institute of Cancer Research. Simple Spit Test Could Finally Turn the Tide on Prostate Cancer. Press release, April 9, 2025. (On PRODICT rollout to diverse populations.)
    https://www.icr.ac.uk/about-us/icr-news/detail/simple-spit-test-could-finally-turn-the-tide-on-prostate-cancer

Informed Prostate Cancer Support Group (IPCSG)  ·  San Diego, California  ·  This article is for patient education only and does not constitute medical advice. Consult your physician for guidance specific to your situation.